TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24286966
Drug: Stimulant Abuser
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant Abuser Groups to Engage in 12-Step (STAGE-12) intervention
Study: 15781758
Drug: Isotretinoin high
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin high dose (1.0 mg/kg per day) for 1 year followed by moderate dose (0.5 mg/kg per day) for 2 years
Study: 15781758
Drug: Isotretinoin moderate
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin moderate dose (0.5 mg/kg per day) for 3 years
Study: 8879891
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of cefdinir once daily (QD) for 10 days
Study: 8879891
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of cefdinir twice daily (BID) for 10 days
Study: 1379664
Drug: Cisplatin 80
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 80 mg/M2 on day 1 and 5-fluorouracil 800 mg/M2 days 2 through 6 (two-drug regimen)
Study: 1379664
Drug: Cisplatin 80
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 80 mg/M2 on day 1, 5-fluorouracil 800 mg/M2 days 2 through 6, plus 15 U bleomycin on day 1 and methotrexate 100 mg/M2 on day 16 followed by 15 mg leucovorin every 6 hours for six doses (four-drug regimen)
Study: 30600702
Drug: HIV-1 vaccine
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-1 vaccine only
Study: 30600702
Drug: IL-2, GM-CSF,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2, GM-CSF, and rhGH immunotherapy with or without vaccine
Study: 25891091
Drug: Triple anti-platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple anti-platelet therapy (TAT; aspirin, clopidogrel, and sarpogrelate)
Study: 25891091
Drug: Conventional dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dual antiplatelet therapy (DAT; aspirin and clopidogrel)
Study: 23663651
Drug: Integrated cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated cognitive behavioral therapy (CBT) - 15 sessions directed at symptom reduction of SUD and ADHD
Study: 23663651
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual - 10 CBT sessions directed at symptom reduction of SUD only
Study: 20303665
Drug: Pregabalin (12-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (12-week treatment)
Study: 17593025
Drug: Low-dose gemtuzumab
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose gemtuzumab ozogamicin (GO) added to FLAI chemotherapy
Study: 17593025
Drug: Low-dose gemtuzumab
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose gemtuzumab ozogamicin (GO)
Study: 17593025
Drug: FLAI chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLAI chemotherapy without GO (historical cohort)
Study: 17966028
Drug: Cast treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cast treatment
Study: 12468610
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplements
Study: 9812128
Drug: Right prefrontal
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right prefrontal transcranial magnetic stimulation at 20 Hz (2-second duration per train, 20 trains/day for 10 treatment days)
Study: 9812128
Drug: Left prefrontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left prefrontal transcranial magnetic stimulation at 20 Hz (2-second duration per train, 20 trains/day for 10 treatment days)
Study: 21729566
Drug: G‐CSF during
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF during the steady rise of the WBC count (5 µg/kg subcutaneously until final PBSC apheresis)
Study: 21729566
Drug: G‐CSF subcutaneously
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF subcutaneously (filgrastim) at the first restoration after the initial nadir of the peripheral WBC count (historical control group)
Study: 16723054
Drug: Prilocaine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prilocaine (300 or 400 mg)
Study: 9376990
Drug: cA2 (chimeric
Approvals — FDA: no, EMA: no, PMDA: no
Description: cA2 (chimeric monoclonal antibody)
Study: 7680852
Drug: Normothermic bypass
Normalized name: factor VIII inhibitor bypassing activity
DrugBank: Anti-inhibitor coagulant complex (DB13151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normothermic bypass and administration of high‐dose aprotinin (2 million IU before CPB, 500,000 IU/h until the end of the operation, and 2 million IU added to the prime)
Study: 3531052
Drug: Trestatin 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trestatin 10 mg
Study: 3531052
Drug: Trestatin 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trestatin 3 mg
Study: 3531052
Drug: Trestatin 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trestatin 50 mg
Study: 24168957
Drug: Aggressive medical
Normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive medical management (antiplatelet therapy, intensive management of vascular risk factors, lifestyle-modification programme)
Study: 20521033
Drug: Dalcetrapib 3,900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalcetrapib 3,900 mg
Study: 15643191
Drug: Topical 0.2%
Normalized name: coal tar topical 0.2% topical soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.2% glyceryl trinitrate (GTN) paste
Study: 7779733
Drug: Accelerated radiotherapy
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated radiotherapy (55 Gy in 32-36 fractions of 1.72-1.53 Gy, twice daily for 3 weeks)
Study: 2264602
Drug: Volunteers for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volunteers for treatment study
Study: 2264602
Drug: Non-volunteers for
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-volunteers for treatment study
Study: 6756508
Drug: Tamoxifen plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen plus CMF chemotherapy
Study: 31654573
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg ARC-520
Study: 31654573
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg ARC-520
Study: 27564385
Drug: Anticholinergic medications
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic medications (AC)
Study: 25380901
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose tacrolimus (group I)
Study: 25380901
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose tacrolimus (group II)
Study: 19594741
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of neoadjuvant hormone therapy (NHT) with goserelin acetate and flutamide before radical prostatectomy (RP)
Study: 17631708
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment plus imported LMWH treatment group
Study: 17631708
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment plus indigenous LMWH treatment group
Study: 15681099
Drug: Carbohydrate drink
Normalized name: Ensure Pre-Surgery Clear Carbohydrate Drink (Strawberry)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate drink (CHOD) 12.6g/100ml, 800 ml evening before surgery and 400 ml on the day of surgery 2-3 hours before anaesthesia.
Study: 15681099
Drug: Placebo drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drink (control group), 800 ml evening before surgery and 400 ml on the day of surgery 2-3 hours before anaesthesia.
Study: 11947915
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg daily for 16 weeks
Study: 11947915
Drug: Gemfibrozil 1200
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemfibrozil 1200 mg daily for 16 weeks
Study: 10487682
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose test (LDT)
Study: 10487682
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose test (SDT)
Study: 6345373
Drug: Nitrendipine 40
Normalized name: nitrendipine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 40 mg
Study: 6345373
Drug: Nitrendipine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (both doses)
Study: 29338073
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of androgen deprivation therapy (ADT)
Study: 26606872
Drug: Sensory approach
Normalized name: aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sensory approach combined with traditional swallowing therapy
Study: 26606872
Drug: Motor approach
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motor approach combined with traditional swallowing therapy
Study: 22595020
Drug: Ubiquinone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubiquinone (400 mg daily for 12 weeks)
Study: 1255309
Drug: Ampicillin treatment
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ampicillin treatment
Study: 31840813
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (SBP target below 120 mm Hg)
Study: 31840813
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (SBP target below 140 mm Hg)
Study: 25008145
Drug: Real tDCS
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real tDCS treatment (2 mA, 35 cm2, two times daily stimulation for 13 min with a 20‐min interval for five consecutive days)
Study: 25008145
Drug: Real tDCS
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real tDCS treatment
Study: 22835219
Drug: DHEA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA supplementation (25 mg three times daily for 3 months)
Study: 19444613
Drug: Acute intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute intake of 15 g of dietary fiber rich in phenolic antioxidants
Study: 17561952
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) at a starting dose of 12.5 mg/day, target dose of 50 mg/day for patients <30 kg and 75 mg/day for patients >30 kg over 4 weeks
Study: 17561952
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) at a starting dose of 10 mg/kg/day, target dose of 20 mg/kg/day over 4 weeks
Study: 17561952
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) at minimum target dose
Study: 10836730
Drug: Valsartan, 80
Normalized name: Valsartan, 80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan, 80 mg, o.d. (AT1 antagonist)
Study: 30626650
Drug: l-serine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-serine (400 mg/kg/day)
Study: 28435240
Drug: Budesonide-containing treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide-containing treatments (budesonide/formoterol or budesonide)
Study: 28435240
Drug: Non-budesonide-containing treatments
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Non-budesonide-containing treatments (formoterol or placebo)
Study: 24909399
Drug: Bipolar transurethral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bipolar transurethral resection of the prostate (B‐TURP) using the TURis system in patients with prostate volume >70 mL
Study: 24909399
Drug: Monopolar transurethral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monopolar transurethral resection of the prostate (M‐TURP) in patients with prostate volume >70 mL
Study: 24909399
Drug: Bipolar transurethral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bipolar transurethral resection of the prostate (B‐TURP) using the TURis system in patients with prostate volume ≤ 70 mL
Study: 23800443
Drug: Supportive text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive text messages delivered twice daily for three months (n=24)
Study: 12868009
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (1 g/day)
Study: 22253969
Drug: High Dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dairy (HD; three dairy servings, diet totaling 1,400 mg/day)
Study: 22253969
Drug: High Calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Calcium (HC; 1,400 mg/day)
Study: 22253969
Drug: Low Calcium
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Calcium (LC; 600 mg/day)
Study: 11434192
Drug: Simvastatin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (both doses)
Study: 10024195
Drug: Self-reported exposures
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported exposures to pesticides, debris from Scuds, chemical and biological warfare agents, and smoke from tent heaters
Study: 8311291
Drug: Both ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both ranitidine 50 mg and metoclopramide 10 mg
Study: 30347089
Drug: Anticoagulant only
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant only
Study: 30347089
Drug: Both aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both aspirin and anticoagulant
Study: 26849409
Drug: Substance abuse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance abuse program contract within a residential drug treatment program
Study: 26849409
Drug: Spent 90
Normalized name: Scented Mayweed Flower
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spent 90 days or greater in a residential drug treatment program
Study: 19151303
Drug: Hydroxyethyl starch
Normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starch (HES) group received 500 mL of saline plus 500 mL of 6% HES 130/0.4
Study: 19151303
Drug: Saline group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline group received 500 mL saline
Study: 16864812
Drug: Chronic Kidney
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic Kidney Disease (CKD) defined by a glomerular filtration rate < or =60 mL/minute/1.73 m2
Study: 15669380
Drug: Pyriproxyfen treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyriproxyfen treatment at 0.01 mg active ingredient/liter
Study: 9129861
Drug: Vaccines for
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccines for the common cold
Study: 8456759
Drug: Lovastatin 20
Normalized name: lovastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 20 mg/day, increased to 40 and 80 mg/day at weeks 6 and 12
Study: 8456759
Drug: Pravastatin 10
Normalized name: pravastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10 mg/day, increased to 20 and 40 mg/day at weeks 6 and 12
Study: 23886644
Drug: S-adenosyl-L-methionine (SAMe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosyl-L-methionine (SAMe) 1.2g daily for 24 weeks
Study: 23886644
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment and placebo arms combined
Study: 12717484
Drug: Molsidomine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (8 mg tid)
Study: 10764316
Drug: 5-lipoxygenase inhibitor
Normalized name: 5-lipoxygenase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-lipoxygenase inhibitor zileuton
Study: 9034259
Drug: Intravenous human
Normalized name: botulism immune globulin IV human Injection [BabyBIG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous human albumin (25 g/day)
Study: 9034259
Drug: Intravenous human
Normalized name: botulism immune globulin IV human Injection [BabyBIG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous human albumin
Study: 31425752
Drug: omega-3 supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: omega-3 supplements (3000 mg)
Study: 31263057
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (81 mg/day)
Study: 28143522
Drug: Standard-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose aspirin (325 mg/day)
Study: 18258794
Drug: 0.15 M
Normalized name: iodine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 M hydrochloric acid (HCl) infusion
Study: 18258794
Drug: 0.075 M
Normalized name: mestranol 0.075 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075 M hydrochloric acid (HCl) infusion
Study: 18258794
Drug: 0.01 M
Normalized name: urea 0.01 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01 M hydrochloric acid (HCl) infusion
Study: 16633299
Drug: Oxaliplatin/infusional 5-FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin/infusional 5-FU combination (OXFU)
Study: 14761117
Drug: R131 allele
Normalized name: Human Factor XIII (A2) homodimer (allele F13A*1B), recombinant DNA origin
Approvals — FDA: no, EMA: no, PMDA: no
Description: R131 allele of the FcgammaR IIa polymorphisms in generalized aggressive periodontitis (G-AP)
Study: 10353936
Drug: Engerix-B vaccine
Normalized name: Engerix-B
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engerix-B vaccine administered at 0-, 1-, and 6-month intervals
Study: 10353936
Drug: Engerix-B vaccine
Normalized name: Engerix-B
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engerix-B vaccine administered at 0-, 12-, and 24-month intervals
Study: 6213349
Drug: 1.0 gm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 gm IV moxalactam every 8 hr for four doses followed by 0.5 gm/kg ethanol
Study: 26088580
Drug: Web-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based cognitive behavioral therapy (CBT)
Study: 11155462
Drug: UDCA 300
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA 300 mg b.i.d. for twelve months
Study: 8469914
Drug: atenolol 50/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol 50/100 mg od
Study: 8469914
Drug: hydrochlorothiazide 25/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrochlorothiazide 25/50 mg + amiloride 5 mg od (co-amiloride)
Study: 3512620
Drug: Transdermal electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal electrical nerve stimulation (TENS)
Study: 24487961
Drug: EMD640744 (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMD640744 (30, 100, and 300 μg doses)
Study: 20728671
Drug: Drugs group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs group assessments
Study: 18988286
Drug: 3 courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 courses of VABEM (vindesine 5 mg/m², doxorubicin 99 mg/m², carmustine 140 mg/m², etoposide 600 mg/m², methylprednisolone 600 mg/m²) followed by low-dose lymph node irradiation
Study: 18988286
Drug: 4 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) followed by myeloablative chemotherapy with carmustine 300 mg/m², etoposide 800 mg/m², cytarabine 1600 mg/m², melphalan 140 mg/m² and autologous stem cell transplantation
Study: 12792504
Drug: Stable-maintenance CsA
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable-maintenance CsA dose (control group)
Study: 7865644
Drug: Enteric coated
Normalized name: Mesasal Enteric Coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated aspirin 300 mg
Study: 1364978
Drug: ACTH (Synacthen)
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH (Synacthen) treatment
Study: 4093902
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of leaflet and tape/slide programme
Study: 31446803
Drug: Antihypertensive drug
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drug classes (6 classes)
Study: 10896910
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone with glutamine (mean 0.12 mg/kg/day and oral mean 28 g/day and parenteral mean 5.2 g/day)
Study: 26888433
Drug: Physical Activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Activity (PA) intervention consisting of 50-minute center-based exercise 2× weekly, augmented with home-based activity to achieve a goal of 150 min/wk of PA
Study: 26888433
Drug: Health education
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health education intervention consisting of weekly workshops for 26 weeks, and monthly sessions thereafter
Study: 25125215
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (70 μg daily for 3 months)
Study: 9620900
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide (NO) inhalation (7 +/- 1 ppm)
Study: 9620900
Drug: Aerosolized prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized prostaglandin E1 (PGE1) inhalation (10 +/- 1 ng/kg/min)
Study: 9620900
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of PGE1 (12 +/- 1 ng/kg/min)